Format

Send to

Choose Destination
Alzheimers Dement. 2015 Sep;11(9):1050-68. doi: 10.1016/j.jalz.2014.09.004. Epub 2014 Nov 24.

The influence of biological and technical factors on quantitative analysis of amyloid PET: Points to consider and recommendations for controlling variability in longitudinal data.

Author information

1
Janssen Pharmaceutica, Beerse, Belgium. Electronic address: mschmid4@its.jnj.com.
2
Biogen IDEC, Cambridge, MA, USA.
3
Synarc, Newark, CA, USA.
4
ADM Diagnostics LLC, Chicago, IL, USA.
5
GE Healthcare, Uppsala, Sweden.
6
Takeda Pharmaceuticals, Deerfield, IL, USA.
7
CereSpir, Inc., New York, NY, USA.
8
Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA, USA.
9
Division of Cognitive Neurology, University of Utah, Salt Lake City, UT, USA.
10
Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA.
11
Piramal Imaging, Boston, MA, USA.
12
Division of Nuclear Medicine, University of Michigan, Ann Arbor, MI, USA.

Abstract

In vivo imaging of amyloid burden with positron emission tomography (PET) provides a means for studying the pathophysiology of Alzheimer's and related diseases. Measurement of subtle changes in amyloid burden requires quantitative analysis of image data. Reliable quantitative analysis of amyloid PET scans acquired at multiple sites and over time requires rigorous standardization of acquisition protocols, subject management, tracer administration, image quality control, and image processing and analysis methods. We review critical points in the acquisition and analysis of amyloid PET, identify ways in which technical factors can contribute to measurement variability, and suggest methods for mitigating these sources of noise. Improved quantitative accuracy could reduce the sample size necessary to detect intervention effects when amyloid PET is used as a treatment end point and allow more reliable interpretation of change in amyloid burden and its relationship to clinical course.

KEYWORDS:

ADNI; Alzheimer's disease; Amyloid; Multi-site trials; Positron emission tomography; Quantitative analysis; Within subject variability

PMID:
25457431
DOI:
10.1016/j.jalz.2014.09.004
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center